Value analysis of CD69 combined with EGR1 in the diagnosis of coronary heart disease

Abstract

Expression and clinical significance of CD69 and early growth response (EGR1) in plasma of patients with coronary heart disease (CHD) were investigated. A total of 194 patients with CHD and 130 healthy subjects, respectively, were selected as CHD and control group, clinical data were collected and coronary angiography was performed. RT-qPCR was used to detect the expression of EGR1. Flow cytometry was used to detect the expression level of CD69 and the receiver operating characteristic curve was used to analyze the values of relative expression of CD69 and EGR1. The relative expression of CD69 in plasma of patients with CHD was higher than that in control group, while the relative expression of EGR1 was lower than that in control group. The relative expression of EGR1 in plasma of patients with CHD was negatively correlated with lipoprotein a [Lp(a)] and high sensitive C-reactive protein (hs-CRP) (r=−0.394 and −0.524, P<0.05), and the relative expression of CD69 in peripheral blood was positively correlated with [Lp(a)] and hs-CRP (r=0.352 and 0.402, P<0.05). The area under curve (AUC) of the relative expression of CD69 in peripheral blood of patients with CHD in evaluating the course of the disease of patients was 0.889 (95% CI: 0.822–0.958). The AUC of the relative expression of EGR1 in plasma in evaluating the course of the disease of patients was 0.933 (95% CI: 0.867–0.978). By the combined detection of CD69 and EGR1, it was found that the AUC was 0.954 (95% CI: 0.887–0.982). The expression level of EGR1 in plasma of patients with CHD decreased, while the expression level of CD69 increased, and both of them were related to the severity of the disease of patients, which could be used as an indicator to evaluate the progression of the patients' conditions.

Identification and verification of feature biomarkers associated in heart failure by bioinformatics analysis

“…According to PPI network analysis, we obtained Hub genes, including EGR1, EGR2, FOS and FOSB. EGR1 is widely present in human cells and has the ability to express rapidly, playing an important role in cell growth, differentiation, proliferation, and inflammatory responses 48 . Studies have shown that inhibiting the expression of EGR1 can slow myocardial fibrosis and thus treat heart failure 49 .…”

Identification of novel prognostic targets in coronary artery disease and related complications using bioinformatics and next generation sequencing data analysis

“…Recent studies have shown that altered expression of DDX58 [413], STAT1 [414], TLR4 [415], CYP2D6 [416], JAK2 [417], TLR2 [418], DUSP6 [419], HDAC9 [420], LATS2 [421], CA2 [150], HIPK3 [422], CCR2 [423], GAB1 [120], UFL1 [424], OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) [425], PRKAR1A [265], SIRT1 [426], FGL2 [427], TET2 [428], ASCC2 [429], BIN1 [430], HSPB1 [431], IGFBP4 [432], TRPM4 [433] and LGALS3 [434] might be associated with the progression of heart failure. STAT1 [435], TLR4 [436], ABCA1 [437], PTGS2 [68], CYP2D6 [438], CR1 [439], PDK4 [440], RNF213 [441], ZDHHC17 [70], TLR8 [442], PDGFC (platelet derived growth factor C) [443], TLR2 [444], CYP1B1 [445], HDAC9 [446], IL1RN [447], GCH1 [448], EGR1 [449], ZEB2 [450], PLA2G7 [451], CCR2 [452], GCLC (glutamate-cysteine ligase catalytic subunit) [258], VEGFA (vascular endothelial growth factor A) [453], CD46 [454], NFKBIZ (NFKB inhibitor zeta) [455], LDLR (low density lipoprotein receptor) [456], TLR6 [457], SIRT1 [458], NOD2 [459], FGL2 [460], IDH1 [461], TET2 [462], PFKFB2 [463], KDM6A [464], IKZF2 [465], ZNF606 [466], PF4 [467], CCR7 [468], RUNX3 [469], TCF7 [470], PPBP (pro-platelet basic protein) [471], IGFBP4 [280], HSPG2 [472] and LGALS3 [236] expression might be regarded as an indicator of susceptibility to CAD. STAT1 [473], TLR4 [367], JAK2 [474], PDGFC (platelet derived growth factor C) […”

“…Previous studies have shown that EGR1 [382], SIRT1 [393], STAT1 [365], HIF1A [383] and IRF9 [390] might influence the prognosis in hypertension. EGR1 [449], SIRT1 [458] and STAT1 [435] are a genes which plays a role in diagnosis of CAD. EGR1 [518] and IRF9 [526] have a significant prognostic potential in ischemic heart disease.…”

“…EGR1 [382], HIF1A [383], STAT1 [365] and FOXP3 [553] mainly involved in the occurrence of hypertension. Aberrant expression of EGR1 [449], STAT1 [435], hsa-mir-16-5p [554], IRF8 [555] and FOXP3 [556] have been observed in CAD. Studies have found that EGR1 [518] and hsa-mir-16-5p [557] expression is an independent predictor of prognosis in patients with ischemic heart disease.…”

Identification of biomarkers, pathways and potential therapeutic targets for heart failure using bioinformatics analysis

“…Hsa-mir-200c-5p [258] and STAT5B [259] were associated with development of diabetics, but these genes might be novel target for HF. EGR1 [260] and GATA2 [261] were liable for advancement of coronary heart disease. FOSB [262] and AHR [263] were associated with development of ischemic cardiac diseases.…”